Drug Trial Radar · NCT02946073
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
Last checked: Nov 19, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,053
Actual
Start
Sep 2016
Primary completion
May 2018
Study completion Feb 2019
Sponsor
- Lead sponsor
- Braeburn PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.; Camurus AB
- First posted
- Oct 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that requires continuous, around-the-clock (ATC) opioid treatment ≥ 40 mg morphine equivalent dose (MED). The study includes 5 phases: A Screening Phase (up to 2 weeks), a Transition Phase (up to 2 weeks), an Open-Label Titration Phase (up to 10 weeks), a Double-Blind Treatment Phase including a Final Study Visit (12 weeks), and a Follow-up Phase (4 weeks). The overall duration of participation in the core phase of the study (randomized Double-Blind Phase) is up to 30 weeks, from the Screening Phase through the Follow-up Phase. Subjects who complete the Double-Blind Treatment Study Phase will be offered an opportunity to continue treatment in an open label safety extension for up to 60 weeks. Additional subjects may be recruited to open label safety extension to meet the goal of 100 subjects with 60 weeks of treatment.
Conditions
- Chronic Lower Back Pain
- Chronic Pain
Interventions
buprenorphineDrug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the Primary Timepoint Will be Week 12 of the Double-Blind Phase.Time frame: 12 weeks- from randomization baseline to 12 weeks after randomization
- Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase.Time frame: 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Locations
69 sites in 1 country. Site status is shown where the registry gives one.
Parkway Medical Center
Birmingham, Alabama
Boyett Health Services Inc
Hamilton, Alabama
National Centers for Pain Management and Research
Vestavia Hills, Alabama
Elite Clinical Studies
Phoenix, Arizona
Phoenix Clinical
Phoenix, Arizona
Noesis Pharma
Phoenix, Arizona
Arizona Research Center
Phoenix, Arizona
MD Studies, Inc.
Fountain Valley, California
Neuro-Pain Medical Center
Fresno, California
Alliance Research Centers
Laguna Hills, California
Clinical Trials Research
Lincoln, California
Catalina Research Institute, LLC
Montclair, California
Allied Clinical Research, LLC
Sacramento, California
Care Practice
San Francisco, California
Syrentis Clinical Research
Santa Ana, California
Universal Pain Management Group
Valencia, California
Tampa Pain Relief Center-Brandon
Brandon, Florida
International Research Partners
Doral, Florida
Dr. Vijapura and Associates
Jacksonville, Florida
Florida Institute of Medical Research
Jacksonville, Florida
Lake Howell Health Center
Maitland, Florida
Ocean Blue Medical Research Center, Inc.
Miami Springs, Florida
Scientific Clinical Research, Inc.
North Miami, Florida
Gold Coast Research, LLC
Plantation, Florida
FMPM Research
St. Petersburg, Florida
Clinical Research of West Florida-Tampa
Tampa, Florida
Tampa Pain Relief Centers-Hillsborough
Tampa, Florida
Palm Beach Research Center
West Palm Beach, Florida
River Birch Research Alliance LLC
Blue Ridge, Georgia
Columbus Regional Research Institute
Knoxville, Georgia
Drug Studies America
Marietta, Georgia
Non-Surgical Orthopedics, P.C.
Marietta, Georgia
Injury Care Research, LLC
Boise, Idaho
Millennium Pain Center
Bloomington, Illinois
Clinical Investigation Specialists, Inc.-Gurnee
Gurnee, Illinois
Medisphere Medical Research Center
Evansville, Indiana
International Clinical Research Institute Inc.
Overland Park, Kansas
Phoenix Medical Research
Prairie Village, Kansas
Otrimed
Edgewood, Kentucky
River Cities Clinical Research Center
Shreveport, Louisiana
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.